GlassScriptPhysician profile
William Fay Esplin
NPI 1093923393
$3,180.55
in general payments reported to CMS, 2019-2025
40 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $336 · 2021: $412 · 2022: $682 · 2023: $470 · 2024: $414 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,003.01 | 2021-2025 | |
| Amgen INC. | $339.21 | 2019-2024 | Krystexxa, Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $169.59 | 2019-2023 | Spravato |
| Pfizer INC. | $156.23 | 2019-2025 | |
| Novo Nordisk INC | $122.47 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $122.10 | 2019-2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Novartis Pharmaceuticals Corporation | $111.44 | 2019-2023 | |
| Amarin Pharma, INC. | $97.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $82.20 | 2020-2023 | Flumist Quadrivalent, Evusheld |
| Lilly USA, LLC | $81.36 | 2020-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $70.62 | 2020-2023 | |
| Dynavax Technologies Corporation | $64.01 | 2019 | |
| Glaxosmithkline, LLC. | $63.30 | 2023-2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.34 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceuticals, INC. | $57.60 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Esplin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.